Sex and Atrial Fibrillation Independently Stratify Cardiac Remodeling and Outcomes in Heart Failure with Preserved

Diana-Ruxandra Hădăreanu1, Flavia-Mihaela Stoiculescu2,3, Călin-Dinu Hădăreanu2,4

  • 1Department of Cardiology, University of Medicine and Pharmacy of Craiova, 2 Petru Rares St., 200349 Craiova, Romania.

Biomedicines
|May 27, 2026
PubMed

Insights

Men with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) face the highest risk of rehospitalization. Understanding sex differences in AF and HFpEF is crucial for risk stratification and patient management.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Clinical Research

Background:

  • Atrial fibrillation (AF) is prevalent in heart failure with preserved ejection fraction (HFpEF), worsening patient outcomes.
  • Emerging evidence suggests sex influences the AF-HFpEF relationship via atrial remodeling, comorbidities, and hemodynamics.

Purpose of the Study:

  • To investigate the combined impact of sex and AF on cardiac structure, clinical features, and prognosis in HFpEF patients.
  • To identify specific risk profiles associated with sex and AF in HFpEF.

Main Methods:

  • Retrospective analysis of 622 HFpEF patients (Jan 2019-May 2023).
  • Patients classified into four groups: women without AF, women with AF, men without AF, and men with AF.
  • Primary endpoint: first rehospitalization for heart failure (HF) decompensation; mean follow-up of 48.6 months.

Main Results:

  • AF independently increased HF rehospitalization risk (HR 1.45). Female sex showed a protective effect (HR 0.71).
  • Men with AF had the highest event burden, adverse remodeling (larger atrial/ventricular dimensions), and lowest survival (HR 1.92).
  • Women with AF showed concentric remodeling and mitral regurgitation; higher NYHA class and lower LVEF predicted rehospitalization.

Conclusions:

  • Sex and AF independently impact HFpEF cardiac structure, clinical characteristics, and prognosis.
  • Men with AF represent the highest-risk HFpEF subgroup due to advanced remodeling and valvular issues.
  • Sex- and rhythm-based classification aids HFpEF risk stratification and management, requiring further validation.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...